Biodesix on Monday announced positive coverage decisions from four private payors -- Blue Cross Blue Shield of North Carolina, Blue Cross Blue Shield of South Carolina, Blue Cross Blue Shield of Kansas City, and Capital District Physician’s Health Plan (CDPHP) of New York.
As a result, the firm’s Nodify XL2 test will now be covered for more than 2.3 million enrollees of Blue Cross of North Carolina, 1.2 million enrollees of Blue Cross Blue Shield of South Carolina, 500,000 enrollees of Blue Cross Blue Shield of Kansas City, and 400,000 enrollees of CDPHP of New York State.
Boulder, CO-based Biodesix develops diagnostic tests by combining multiomics through artificial intelligence. Nodify XL2 is a blood-based proteomic test to help healthcare professionals quickly identify patients with likely-benign lung nodules who may benefit from the use of computed tomography surveillance. Clinical validation studies showed that the test has a 98% negative predictive value, helping healthcare professionals avoid unnecessary interventional procedures on benign lung nodules, the firm said.
“At Biodesix we have a comprehensive suite of five on-market precision diagnostics to support clinical decision-making across the lung cancer continuum of care,” Scott Hutton, CEO of Biodesix, said in a statement. “While all five of the tests in our core lung diagnostic testing portfolio are covered by Medicare, we have been anticipating the first private payer coverage policies.”
